Bundred Nigel J, Anderson Elizabeth, Nicholson Robert I, Dowsett Mitchell, Dixon Michael, Robertson John F
Department of Surgery, South Manchester University Hospital Education and Research Centre, UK.
Anticancer Res. 2002 Jul-Aug;22(4):2317-9.
BACKGROUND: This study was performed to determine whether drug action on breast tumours could also be analysed using a cell turnover index (CTI), a composite measurement of both proliferation and apoptosis. MATERIALS AND METHODS: Data were obtained from a randomized, placebo-controlled trial comparing three single doses (50, 125 and 250 mg) of intramuscular fulvestrant (Faslodex, previously known as ICI 182,780) with oral tamoxifen 20 mg/day for 14-21 days in women with early, operable, ER-positive breast cancer. CTI was calculated as the ratio of the proliferation index to the apoptotic index. RESULTS: Fulvestrant 250 mg significantly reduced CTI compared with both placebo (p = 0.0003) and tamoxifen (p = 0.026). The effect on CTI with tamoxifen was not significantly different from that with placebo. CONCLUSION: This study suggests that CTI may be a useful indicator of drug action on breast tumour growth. A significant reduction in growth was found with fulvestrant 250 mg compared with tamoxifen.
背景：本研究旨在确定是否也可以使用细胞更新指数（CTI）来分析药物对乳腺肿瘤的作用，CTI是增殖和凋亡的综合测量指标。 材料与方法：数据来自一项随机、安慰剂对照试验，该试验比较了三种单剂量（50、125和250mg）的肌肉注射氟维司群（芙仕得，先前称为ICI 182,780）与口服他莫昔芬20mg/天，持续14 - 21天，用于早期、可手术、雌激素受体阳性乳腺癌女性。CTI计算为增殖指数与凋亡指数之比。 结果：与安慰剂（p = 0.0003）和他莫昔芬（p = 0.026）相比，250mg氟维司群显著降低了CTI。他莫昔芬对CTI的影响与安慰剂无显著差异。 结论：本研究表明CTI可能是药物对乳腺肿瘤生长作用的有用指标。与他莫昔芬相比，250mg氟维司群使肿瘤生长显著降低。
J Steroid Biochem Mol Biol. 2006-3
Breast Cancer Res Treat. 2003-9
J Steroid Biochem Mol Biol. 2001-12
Pharmacol Rev. 2013-3-1
Zotero 插件